Key result
CRP-STEMI evaluates selective CRP apheresis to reduce infarct size after PCI.
Why the study?
Myocardial salvage after STEMI treated with primary PCI is often incomplete, and selective CRP apheresis may reduce infarct size by targeting inflammation.
Does selective C-reactive protein apheresis in addition to standard care reduce infarct size in STEMI patients undergoing PCI within 12 hours of symptom onset?
RCT (n=202)
Open-label (outcome assessor blinded)
1:1
Yes
Does selective C-reactive protein apheresis in addition to standard care reduce infarct size in STEMI patients undergoing PCI within 12 hours of symptom onset?
Answers are grounded in this paper and cite their sources.
The CRP-STEMI trial is designed to investigate whether selective CRP apheresis reduces infarct size in STEMI patients undergoing primary PCI.
BACKGROUND: Despite the effectiveness of primary percutaneous coronary intervention (PCI) in treating ST-elevation myocardial infarction (STEMI), myocardial salvage is often incomplete, resulting in large infarct size and an increased risk of heart failure and mortality. Inflammation is involved in this process, with C-reactive protein (CRP) potentially contributing to infarct expansion. Whether selective CRP apheresis in addition to standard care can reduce infarct size in STEMI remains to be determined. TRIAL DESIGN: Selective C-reactive protein apheresis in ST-elevation myocardial infarction (CRP-STEMI) is an investigator-initiated, randomized, open-label (outcome assessor blinded), multicenter trial investigating whether selective CRP apheresis using the PentraSorb-CRP system, in addition to standard care, can reduce infarct size in STEMI patients undergoing PCI within 12 hours of symptom onset. The trial will enroll 202 patients at 5 tertiary care centers in Austria and Germany, randomized 1:1 to either the intervention group (standard care + CRP apheresis) or the control group (standard care). In the intervention group, CRP apheresis will be performed on days 1, 2, and 3 post-PCI. The primary endpoint is infarct size as assessed by late gadolinium enhanced cardiac magnetic resonance at 5 ± 2 days after PCI. OUTLOOK: CRP-STEMI is the first randomized trial to investigate whether selective CRP apheresis, as an adjunct to standard care, can effectively reduce infarct size in acute STEMI patients. TRIAL REGISTRATION: CRP-STEMI, NCT04939805, is registered at https://clinicaltrials.gov/study/NCT04939805.
No takes yet. Share an insight, caveat, or question.
Reinstadler et al. (2025) conducted an RCT in ST-elevation myocardial infarction (STEMI) (n=202). Selective C-reactive protein (CRP) apheresis vs. Standard care was evaluated on Infarct size as assessed by late gadolinium enhanced cardiac magnetic resonance at 5 ± 2 days after PCI. The CRP-STEMI trial is designed to evaluate whether selective CRP apheresis in addition to standard care reduces infarct size in STEMI patients undergoing PCI.
Synapse has enriched 10 related papers. Consider them for comparative context: